770
Views
17
CrossRef citations to date
0
Altmetric
Review

Drug-induced parkinsonism: diagnosis and management

&
Pages 83-91 | Published online: 23 Sep 2016

References

  • Friedman JH, Trieschmann ME, Fernandez HH. Chap. 6: Drug-induced parkinsonism. In: Factor SA, Lang AE, Weiner WJ, editors. Drug Induced Movement Disorders. 2nd ed. Madden, MA: Blackwell Publishing; 2005:103–139.
  • Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009;85(1004):322–326.
  • López-Sendón J, Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf. 2013;12(4):487–496.
  • Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord. 2006;21(6):800–808.
  • Bergouignan M, Régnier G. Aspect parkinsonien réversible au cours d’une cure de Largactil pour vomissements gravidiques [Reversible parkinsonism in the course of largactil therapy of vomiting in pregnancy]. J Med Bord. 1954;131(7):678–679.
  • Steck H. Le syndrome extrapyramidal et diencéphalique au cours des traitements au largactil et au serpasil [Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments]. Ann Med Psychol (Paris). 1954;112(25):737–744.
  • Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226–2231.
  • Wilson JA, MacLennan WJ. Review: drug-induced parkinsonism in elderly patients. Age Ageing. 1989;18(3):208–210.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth ed. Arlington, VA: American Psychiatric Association; 2013.
  • Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–752.
  • Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19.
  • Blanchet PJ, Rompré PH. Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia. J Clin Psychopharmacol. 2014;34(1):36–39.
  • Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. 2008;23(3):401–404.
  • Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009;17(3):255–263.
  • Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA. 1961;175:1054–1060.
  • Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226–2231.
  • Silver M, Factor SA. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord. 2013;19(8):758–760.
  • Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52(6):1214–1220.
  • Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord. 2002;17(5):910–916.
  • Shuaib UA, Rajput AH, Robinson CA, Rajput A. Neuroleptic-induced parkinsonism: clinicopathological study. Mov Disord. 2016;30(3):360–365.
  • de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology. 1997;48(5):1277–1281.
  • Hall RA, Jackson RB, Swain JM. Neurotoxic reactions resulting from chlorpromazine administration. J Am Med Assoc. 1956;161(3):214–218.
  • Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM. Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18(3):267–274.
  • Gershanik OS. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging. 1994;5(2):127–132.
  • Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol. 1983;6(Suppl 1):S9–S26.
  • Llau ME, Nguyen L, Senard JM, Rascol O, Montastruc JL. Syndromes parkinsoniens d’origine médicamenteuse: expérience d’un centre régional de pharmacovigilance sur dix ans [Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance]. Rev Neurol (Paris). 1994;150(11):757–762.
  • Errea-Abad JM, Ara-Callizo JR, Aibar-Remón C. Parkinsonismo inducido por fármacos. Aspectos clínicos comparativos con la enfermedad de Parkinson [Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease]. Rev Neurol. 1998;27(155):35–39.
  • Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol. 2005;4(12):815–820.
  • Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol. 1999;19(4):322–328.
  • Demars JP. Neuromuscular effects of long-term phenothiazine medication, electroconvulsive therapy and leucotomy. J Nerv Ment Dis. 1966;143(1):73–79.
  • McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673–678.
  • Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry. 1991;148(11):1558–1561.
  • Chakos M, Mayerhoff D, Loebel A, Alvir J, Lieberman J. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull. 1992;28(1):81–86.
  • Bovi T, Antonini A, Ottaviani S, et al. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J Neurol. 2010;257(11):1882–1889.
  • Morley JF, Pawlowski SM, Kesari A, Maina I, Pantelyat A, Duda JE. Motor and non-motor features of Parkinson’s disease that predict persistent drug-induced parkinsonism. Parkinsonism Relat Disord. 2014;20(7):738–742.
  • Myrianthopoulos NC, Kurland AA, Kurland LT. Hereditary predisposition in drug-induced parkinsonism. Arch Neurol. 1962;6(1):5–9.
  • Rao JM, Cowie VA, Mathew B. Neuroleptic-induced parkinsonian side effects in the mentally handicapped. J Ment Defic Res. 1989;33(pt 1):81–86.
  • Knol W, van Marum RJ, Jansen PA, et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol. 2013;33(3):405–410.
  • Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16(1):23–45.
  • Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol. 2016;29(4):227–236.
  • Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
  • Lutz UC, Sirfy A, Wiatr G, et al. Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders. Eur J Clin Pharmacol. 2014;70(12):1471–1476.
  • Chen S, Seeman P, Liu F. Antipsychotic drug binding in the substantia nigra: an examination of high metoclopramide binding in the brains of normal, Alzheimer’s disease, Huntington’s disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia. Synapse. 2011;65(2):119–124.
  • Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf. 2006;5(6):759–771.
  • Kuzuhara S. [Drug-induced parkinsonism]. Nihon Rinsho. 1997;55(1):112–117.
  • Marras C, Herrmann N, Fischer HD, et al. Lithium use in older adults is associated with increased prescribing of Parkinson medications. Am J Geriatr Psychiatry. 2016;24(4):301–309.
  • Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology. 2004;62(8):1435–1437.
  • Ristić AJ, Vojvodić N, Janković S, Sindelić A, Sokić D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006;47(12):2183–2185.
  • Mahmoud F, Tampi RR. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatr Pharmacother. 2011;9(6):405–412.
  • Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry. 2010;22(3):148–156.
  • Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother. 2015;49(10):1136–1152.
  • Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995;15(1 pt 2):821–829.
  • Huot P, Johnston TH, Fox SH, Brotchie JM. Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study. Synapse. 2015;69(3):99–102.
  • Peroutka SJ. Chemotherapeutic agents do not interact with neurotransmitter receptors. Cancer Chemother Pharmacol. 1987;19(2):131–132.
  • Madhyastha S, Somayaji SN, Rao MS, Nalini K, Bairy KL. Effect of intracerebroventricular methotrexate on brain amines. Indian J Physiol Pharmacol. 2005;49(4):427–435.
  • van Pelt-Sprangers MJ, Geijteman EC, Alsma J, Boere IA, Mathijssen RH, Schuit SC. Oromandibular dystonia: a serious side effect of capecitabine. BMC Cancer. 2015;15:115.
  • Crystal SC, Leonidas J, Jakubowski A, Di Rocco A. Thalidomide induced acute worsening of Parkinson’s disease. Mov Disord. 2009;24(12):1863–1864.
  • Smith CP, Oh JD, Bibbiani F, Collins MA, Avila I, Chase TN. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology. 2007;52(2):515–526.
  • Hassin-Baer S, Sirota P, Korczyn AD, et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm (Vienna). 2001;108(11):1299–1308.
  • Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51(6):850–854.
  • Lee PH, Yeo SH, Yong SW, Yun JK. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2007;78(11):1250–1252.
  • Howell MJ. Parasomnias: an updated review. Neurotherapeutics. 2012;9(4):753–775.
  • Kim JS, Youn J, Shin H, Cho JW. Nonmotor symptoms in drug-induced parkinsonism and drug-naïve Parkinson disease. Can J Neurol Sci. 2013;40(1):36–41.
  • Vasudev A, Shariff SZ, Liu K, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004–2013. Am J Geriatr Psychiatry. 2015;23(12):1259–1269.
  • Fann WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry. 1976;133(8):940–943.
  • Friedman JH. Managing idiopathic Parkinson’s disease in patients with schizophrenic disorders. Parkinsonism Relat Disord. 2011;17(3):198–200.
  • Klawans HL, Gegen D, Bruyn GW. Prolonged drug-induced parkinsonism. Confin Neurol. 1973;35:368–377.
  • Martí-Massó JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord. 1998;13(3):453–456.
  • Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014;20(8):808–814.
  • Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology. 2012;79(15):1615–1621.
  • Tinazzi M, Cipriani A, Matinella A, et al. [123I]FP- CIT single photon emission computed tomography findings in drug-induced parkinsonism. Schizophr Res. 2012;139(1–3):40–45.
  • Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord. 2015;30(6):780–785.
  • Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007;48(2):205–211.
  • Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395–406.
  • Jauss M, Krack P, Franz M, et al. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord. 1996;11(6):726–728.
  • Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41–47.